IPO - NEKTAR THERAPEUTICS

Form Type: 424B5

Filing Date: 2025-06-30

Corporate Action: Ipo

Type: New

Accession Number: 000119312525152827

Filing Summary: Nektar Therapeutics is offering shares of common stock and pre-funded warrants in a public offering. The pre-funded warrants will allow investors to purchase shares of common stock, and they will be exercisable immediately. As of June 27, 2025, the last reported sale price for the company's common stock was $25.76. Nektar depicts itself as a clinical-stage biopharmaceutical company with a focus on immunotherapy, targeting autoimmune diseases and cancer. Their development pipeline includes drug candidates like rezpegaldesleukin and NKTR-255, aimed at restoring immune balance and enhancing cancer treatment. Recently, they announced positive topline results from their Phase 2b clinical trial on rezpegaldesleukin for treating atopic dermatitis, achieving primary and secondary endpoints with statistical significance. Additionally, a reverse stock split was conducted at a ratio of one-for-fifteen, effective June 8, 2025, to increase the number of authorized shares from 300 million to 390 million. The offering is part of a shelf registration process and introduces a high degree of investment risk.